Starsource Multitrade

Starsource Multitrade EBITDA

EBITDA (Resultat før renter, skatter, av- og nedskrivninger) av Starsource Multitrade (506365.BO) per 16. okt. 2026 er −53 940,00 INR. Forrige år var EBITDA (Resultat før renter, skatter, av- og nedskrivninger) −1,16 M INR — en endring på −95,36% (høyere).

EBITDA

−53 940,00INR

YoY

−95,36%

Sist oppdatert:

EBITDA (Resultat før renter, skatter, av- og nedskrivninger) av Starsource Multitrade er 2026 −53 940,00 INR. EBITDA (Resultat før renter, skatter, av- og nedskrivninger) av Starsource Multitrade var 2025 −1,16 M INR. Den faller med −95,36% høyere sammenlignet med året før.

Starsource Multitrade EBITDA historikk

  • 3 år

  • 10 år

  • 25 år

  • Maks

EBITDA
Dato
EBITDA
1. jan. 2019
−5,67 M INR
1. jan. 2020
−4,65 M INR
1. jan. 2021
−1,61 M INR
1. jan. 2022
−4,24 M INR
1. jan. 2023
−2,09 M INR
1. jan. 2024
−1,86 M INR
1. jan. 2025
−1,16 M INR
1. jan. 2026
−53 940,00 INR
Starsource Multitrade EBITDA historikk
ÅREBITDAYoY
−53 940,00INR−95,36%
−1,16 MINR−37,57%
−1,86 MINR−10,77%
−2,09 MINR−50,72%
−4,24 MINR+163,67%
−1,61 MINR−65,45%
−4,65 MINR−18,02%
−5,67 MINR+77,08%
−3,20 MINR+53,65%
−2,09 MINR−165,45%
3,19 MINR−21,35%
4,05 MINR+29,33%
3,13 MINR—

Hent disse dataene via Eulerpool API

100 000 kall/mnd gratis · ingen kredittkort

Starsource Multitrade Aksjeanalyse

Hva gjør Starsource Multitrade? Starsource Multitrade Ltd, identified by the ticker symbol 506365.BO and ISIN INE320M01019, is a corporate entity registered in India with its headquarters located in Mumbai, Maharashtra. The company was originally established through an initial public offering on January 2, 1995. While the specific sector and industry classifications are currently listed as not applicable, the company's operational history and strategic direction are closely tied to its former identity as Chemo Pharma Laboratories Ltd. This previous incarnation operated within the pharmaceutical industry, focusing on the development and distribution of healthcare products. However, the corporate landscape has shifted significantly, and the entity is no longer engaged in its original pharmaceutical activities. According to available information, the firm currently has no active operations within its traditional business lines. Instead, the organization is in a transitional phase, actively exploring new business opportunities to redefine its market presence. The strategic intent of the current management is to pivot away from pharmaceuticals and acquire businesses in the power and chemicals sectors. This move represents a substantial change in the company's core focus, aiming to diversify its portfolio and enter entirely different industrial segments. The company's official website, https://www.thechemopharmalaboratoriesltd.com/, reflects its historical branding, although the operational reality has evolved. Investors and stakeholders monitoring the company should note that the absence of current operations means that recent financial performance may not reflect traditional revenue streams associated with pharmaceutical manufacturing or sales. The focus is currently on strategic acquisitions and business development rather than organic growth from existing products. The transition from a pharmaceutical manufacturer to a holding or investment vehicle targeting power and chemical assets suggests a long-term restructuring plan. Until new acquisitions are finalized and integrated, the company remains in a state of exploration and preparation. The headquarters in Mumbai serves as the administrative center for these strategic discussions and future operational planning. The lack of a defined sector classification further underscores the company's current status as an entity in flux, waiting for new business units to be acquired and operationalized. This profile highlights the significant shift from its historical roots in healthcare to its current ambitions in energy and industrial chemicals, marking a distinct chapter in the company's corporate evolution. Starsource Multitrade er et av de mest populære selskapene på Eulerpool.

Ofte stilte spørsmål om Starsource Multitrade aksje

EBITDA (Resultat før renter, skatter, av- og nedskrivninger) for Starsource Multitrade er −53 940,00 INR i 2026.

EBITDA (Resultat før renter, skatter, av- og nedskrivninger) av Starsource Multitrade endret seg fra −1,16 M INR til −53 940,00 INR, som representerer en −95,36% endring. Verdien er høyere enn forrige år.

På Eulerpool finner du den komplette historiske utviklingen av EBITDA (Resultat før renter, skatter, av- og nedskrivninger) Starsource Multitrade siden 2006 – med årlige verdier, diagrammer og detaljert analyse.

EBITDA måler operativ ytelse før påvirkning av finansieringsstruktur, skatteklimaet og ikke-kontantbaserte avskrivninger.

EBITDA = EBIT + Av- og nedskrivninger

EBITDA (Resultat før renter, skatter, av- og nedskrivninger)s INR er en nøkkelfaktor for investorer. Endringer i denne metrikken kan signalisere forbedring eller forverring av fundamentale forhold, noe som direkte påvirker aksjekursen. På Eulerpool kan du spore EBITDA (Resultat før renter, skatter, av- og nedskrivninger)s Starsource Multitrade historisk og i sanntid.

Hent disse dataene via Eulerpool API

100 000 kall/mnd gratis · ingen kredittkort

Resultatregnskap — Starsource Multitrade

Alle nøkkeltall — Starsource Multitrade